ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
EF-19 data confirm the effectiveness and safety of Optune as monotherapy and further strengthen Optune’s clinical profile in recurrent GBM The FDA-mandated EF-19 post-approval registry trial studied ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
NovoCure's product, the Optune, is an oncology therapy that's unlike others on the market. It's a wearable device that emits tumor treating fields of electromagnetic energy. Those fields interfere ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results